Skip to main content
SpringerLink
Log in

Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells

  • Original articles
  • Published:
Cancer Immunology, Immunotherapy Aims and scope Submit manuscript

Abstract

Adherent lymphokine-activated killer (A-LAK) cells were obtained from peripheral blood lymphocytes of patients with recurrent glioblastoma. In vitro features of A-LAK cultures were assessed in comparison to those of non-adherent lymphokine-activated killer (NA-LAK) cells of the same patients with regard to cytotoxic activity, proliferation and surface markers. Only in a minority of cases did A-LAK cells show a markedly higher cytotoxicity on K562, Daudi and allogeneic glioblastoma cells. Nevertheless, A-LAK cells proliferated significantly better than NA-LAK and contained higher percentages of CD16+, CD56+ and CD25+ cells, indicating that A-LAK cells from these patients represent a subpopulation of lymphocytes enriched for activated natural killer cells. We also investigated whether immunosuppressive factor(s) were present in the tumour bed of recurrent gliomas. To this end, samples of glioblastoma cavity fluid (GCF), which accumulates in the cavity of subtotally removed tumour, were recovered and tested for the presence of immunosuppressive activity. All GCF samples analysed were shown to inhibit in vitro proliferation and antitumour cytotoxicity of 1-week-cultured A-LAK cells in a dose-dependent manner. Such GCF activity was effectively antagonized by a transforming growth factor β (TGFβ) neutralizing antibody, indicating the involvement of TGFβ in lymphocyte inhibition. These results show that in the tumour cavity remaining after subtotal glioblastoma resection a marked immunosuppressive activity, probably due to local release of TGFβ, is present; such activity may negatively influence the therapeutic effectiveness of local cellular immunotherapy.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Bodmer S, Strommer K, Frei K, Siepl C, de Tribolet N, Heid I, Fontana A (1989) Immunosuppression and transforming growth factor-β in glioblastoma. Preferential production of transforming growth factor-β2. J Immunol 143: 3222

    Google Scholar 

  2. Brooks WH, Netsky MG, Normansell DE, Horwitz DA (1972) Depressed cell-mediated immunity in patients with primary intracranial tumors. J Exp Med 136: 1631

    Google Scholar 

  3. De Martin R, Haendler B, Hofer-Warbinek R, Gaugitsch H, Wrann M, Schlusener H, Seifert JM, Bodmer S, Fontana A, Hofer E (1987) Complementary DNA for human glioblastoma-derived T cell suppressor factor, a novel member of the transforming growth factor-β gene family. EMBO J 6: 3673

    Google Scholar 

  4. Elliott LH, Brooks WH, Roszman TL (1992) Suppression of high affinity IL-2 receptors on mitogen activated lymphocytes by gliomaderived suppressor factor. J Neurooncol 14: 1

    Google Scholar 

  5. Espevik T, Figari IS, Ranges GE, Palladino MA Jr (1988) Transforming growth factor-β1 (TGF-β1) and recombinant human tumor necrosis factor-α reciprocally regulate the generation of lymphokineactivated killer cell activity. Comparison between natural porcine platelet-derived TGF-β1 and TGF-β2, and recombinant human TGF-β1. J Immunol 140: 2312

    Google Scholar 

  6. Fontana A, Hengartner H, de Tribolet N, Weber E (1984) Glioblastoma cells release interleukin-1 and factors inhibiting interleukin-2 mediated effects. J Immunol 132: 1837

    Google Scholar 

  7. Fontana A, Frei K, Bodmer S, Hofer E, Schreier MH, Palladino MA Jr, Zinkernagel RM (1989) Transforming growth factor-β inhibits the generation of cytotoxic T cells in virus-infected mice. J Immunol 143: 323

    Google Scholar 

  8. Inge TH, Hoover SK, Susskind BM, Barrett SK, Bear HD (1992) Inhibition of tumor-specific cytotoxic T-lymphocyte responses by transforming growth factor-β1. Cancer Res 52: 1386

    Google Scholar 

  9. Ioli G, Yamamoto R, Jacques D, Neal J, Granger G (1992) Blocking factors (soluble receptors) for human TNF and LT in the serum, cerebrospinal fluid (CSF) and tumor cyst fluid (TCF) of human glioma patients. Proc Am Assoc Cancer Res 33: 309

    Google Scholar 

  10. Jaaskelainen J, Kalliomaki P, Paetau A, Timonen T (1989) Effect of LAK cells against three-dimensional tumor tissue. In vitro study using multi-cellular human glioma spheroids as targets. J Immunol 142: 1036

    Google Scholar 

  11. Jaaskelainen J, Maenpaa A, Patarroyo M, Gahmberg CG, Somersalo K, Tarkkanen J, Kallio M, Timonen T (1992) Migration of recombinant IL-2-activated T and natural killer cells in the intercellular space of human H-2 glioma spheroids in vitro. A study on adhesion molecules involved. J Immunol 149: 260

    Google Scholar 

  12. Jaeckle KA, Mittelman A, Hill FH (1990) Phase II trial ofSerratia marcescens extract in recurrent malignant astrocytoma. J Clin Oncol 8: 1408

    Google Scholar 

  13. Kehrl JH, Wakefield LM, Roberts AB, Jakowlew S, Alvarez-Mon M, Derynck R, Sporn MB, Fauci AS (1986) Production of transforming growth factor-β by human T lymphocytes and its potential role in the regulation of T cell growth. J Exp Med 163: 1037

    Google Scholar 

  14. Kuppner MC, Hamou MF, Bodmer S, Fontana A, de Tribolet N (1988) The glioblastoma-derived T-cell suppressor factor/transforming growth factor-β2 inhibits the generation of lymphokine-activated killer (LAK) cells. Int J Cancer 42: 562

    Google Scholar 

  15. Kuppner MC, Hamou MF, Sawamura Y, Bodmer S, de Tribolet N (1989) Inhibition of lymphocyte function by glioblastoma-derived transforming growth factor-β2. J Neurosurg 71: 211

    Google Scholar 

  16. Kuppner MC, Sawamura Y, Hamou MF, de Tribolet N (1990) Influence of PGE2 and cAMP-modulating agents on human glioblastoma cell killing by interleukin-2 activated lymphocytes. J Neurosurg 72: 619

    Google Scholar 

  17. Mahaley MS, Brooks WH, Roszman TL, Bigner DD, Dudka L, Richardson S (1977) Immunobiology of primary intracranial tumors. Part I. Studies of the cellular and humoral general immune competence of brain tumor patients. J Neurosurg 46: 467

    Google Scholar 

  18. Melder RJ, Whiteside TL, Vujanovic NL, Hiserodt JC, Herberman RB (1988) A new approach to generating antitumor effectors for adoptive immunotherapy using adherent lymphokine-activated killer cells. Cancer Res 48: 3461

    Google Scholar 

  19. Merchant RE, Ellison MD, Young HF (1990) Immunotherapy for malignant glioma using human recombinant interleukin-2 and activated autologous lymphocytes. A review of preclinical and clinical investigations. J Neurooncol 8: 173

    Google Scholar 

  20. Mulé JJ, Schwarz SL, Roberts AB, Sporn MB, Rosenberg SA (1988) Transforming growth factor-β inhibits the in vitro generation of lymphokine-activated killer cells and cytotoxic T cells. Cancer Immunol Immunother 26: 95

    Google Scholar 

  21. Nitta T, Sato K, Yagita H, Okumura K, Ishii S (1990) Preliminary trial of specific targeting therapy against malignant glioma. Lancet 335: 368

    Google Scholar 

  22. Palma L, Di Lorenzo N, Guidetti B (1978) Lymphocyte infiltrates in primary glioblastomas and recidivous gliomas. Incidence, fate and relevance to prognosis in 228 operated cases. J Neurosurg 49: 854

    Google Scholar 

  23. Ranges GE, Figari IS, Espevik T, Palladino MA Jr (1987) Inhibition of cytotoxic T cell development by transforming growth factor-β and reversal by recombinant tumor necrosis factor α. J Exp Med 166: 991

    Google Scholar 

  24. Rivoltini L, Cattoretti G, Arienti F, Mastroianni A, Melani C, Colombo MP, Parmiani G (1991) The high lysability by LAK cells of colon-carcinoma cells resistant to doxorubicin is associated with a high expression of ICAM-1, LFA-3, NCA and a less-differentiated phenotype. Int J Cancer 47: 746

    Google Scholar 

  25. Rivoltini L, Arienti F, Orazi A, Cefalo G, Gasparini M, Gambacorti-Passerini C, Fossati-Bellani F, Parmiani G (1992) Phenotypic and functional analysis of lymphocytes infiltrating paediatric tumors, with a characterization of the tumor phenotype. Cancer Immunol Immunother 34: 241

    Google Scholar 

  26. Rook AH, Kehrl JH, Wakefield LM, Roberts AB, Sporn MB, Burlington DB, Lane HC, Fauci AS (1986) Effects of transforming growth factor-β on the functions of natural killer cells: depressed cytolytic activity and blunting of interferon responsiveness. J Immunol 136: 3916

    Google Scholar 

  27. Roszman T, Elliott L, Brooks W (1991) Modulation of T-cell function by gliomas. Immunol Today 12: 370

    Google Scholar 

  28. Sander B, Andersson J, Andersson U (1991) Assessment of cytokines by immunofluorescence and the paraformaldehyde-saponin procedure. Immunol Rev 119: 65

    Google Scholar 

  29. Sawamura Y, Diserens AC, de Tribolet N (1990) In vitro prostaglandin E2 production by glioblastoma cells and its effect on interleukin-2 activation of oncolytic lymphocytes. J Neurooncol 9: 125

    Google Scholar 

  30. Schuster JM, Bigner DD (1992) Immunotherapy and monoclonal antibody therapies. Curr Opin Oncol 4: 547

    Google Scholar 

  31. Schwarz RE, Vujanovic NL, Hiserodt JC (1989) Enhanced antimetastatic activity of lymphokine-activated killer cells purified and expanded by their adherence to plastic. Cancer Res 49: 1441

    Google Scholar 

  32. Schwyzer M, Fontana A (1985) Partial purification and biochemical characterization of a T cell suppressor factor produced by human glioblastoma cells. J Immunol 134: 1003

    Google Scholar 

  33. Siepl C, Bodmer S, Frei K, Robson MacDonald H, De Martin R, Hofer E, Fontana A (1988) The glioblastoma-derived T cell suppressor factor/transforming growth factor-β2 inhibits T cell growth without affecting the interaction of interleukin-2 with its receptor. Eur J Immunol 18: 593

    Google Scholar 

  34. Smyth MJ, Strobl SL, Young HA, Ortaldo JR, Ochoa AC (1991) Regulation of lymphokine-activated killer activity and pore-forming protein gene expression in human peripheral blood CD8+ T lymphocytes. Inhibition by transforming growth factor-β. J Immunol 146: 3289

    Google Scholar 

  35. Torre-Amione G, Beauchamp RD, Koeppen H, Park BH, Schreiber H, Moses HL, Rowley DA (1990) A highly immunogenic tumor transfected with a murine transforming growth factor type β1 cDNA escapes immune surveillance. Proc Natl Acad Sci USA 87: 1486

    Google Scholar 

  36. Ushio Y (1991) Treatment of gliomas in adults. Curr Opin Oncol 3: 467

    Google Scholar 

  37. Whiteside TL, Wang YL, Selker RG, Herberman RB (1988) In vitro generation and antitumor activity of adherent lymphokine-activated killer cells from the blood of patients with brain tumors. Cancer Res 48: 6069

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Experimental Oncology D, Istituto Nazionale Tumori, Via Venezian 1, I-20 133, Milan, Italy

    Pier Adelchi Ruffini, Licia Rivoltini & Giorgio Parmiani

  2. Division of Neurology, Istituto Nazionale Neurologico “C. Besta”, Milan, Italy

    Antonio Silvani & Amerigo Boiardi

Authors
  1. Pier Adelchi Ruffini
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Licia Rivoltini
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Antonio Silvani
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Amerigo Boiardi
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Giorgio Parmiani
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Ruffini, P.A., Rivoltini, L., Silvani, A. et al. Factors, including transforming growth factor β, released in the glioblastoma residual cavity, impair activity of adherent lymphokine-activated killer cells. Cancer Immunol Immunother 36, 409–416 (1993). https://doi.org/10.1007/BF01742258

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF01742258

Key words

Search

Navigation